

# Roy F P M Kruitwagen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3020644/publications.pdf>

Version: 2024-02-01

114  
papers

3,843  
citations

136950

32  
h-index

144013

57  
g-index

116  
all docs

116  
docs citations

116  
times ranked

5247  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study. <i>Journal of Immunotherapy</i> , 2022, 45, 180-186.	2.4	13
2	Ovarian cancer ascites induces skeletal muscle wasting <i>in vitro</i> and reflects sarcopenia in patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 311-324.	7.3	8
3	An overview of Clinical Quality Registries (CQRs) on gynecological oncology worldwide. <i>European Journal of Surgical Oncology</i> , 2022, 48, 2094-2103.	1.0	1
4	The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	11
5	The ENSURE trial for women with low-risk, early-stage endometrial cancer: A randomized controlled trial comparing the effect of a reduced (4 visits/3 yr) versus usual (8-11 visits/3 yr) follow-up schedule on patient satisfaction, health care use, and disease perception.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5586-5586.	1.6	0
6	Frozen section diagnosis of borderline ovarian tumors with suspicious features of invasive cancer is a devil's dilemma for the surgeon: A systematic review and meta-analysis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1369-1376.	2.8	9
7	Pharmacological inhibition of 17 $\beta$ -hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model. <i>Cancer Letters</i> , 2021, 508, 18-29.	7.2	4
8	Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data. <i>Cancer Epidemiology</i> , 2021, 75, 102008.	1.9	0
9	Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 2007-2021.	7.3	56
10	Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2021, 14, 139.	3.0	2
11	Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?. <i>Journal of Ovarian Research</i> , 2021, 14, 132.	3.0	15
12	What do we need to know about anatomy in gynaecology: A Delphi consensus study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 245, 56-63.	1.1	8
13	Short-term surgical complications after radical hysterectomyâA nationwide cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 925-932.	2.8	11
14	Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1165-1174.	7.3	108
15	Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989â2015. <i>European Journal of Cancer</i> , 2019, 118, 97-104.	2.8	16
16	Feasibility of sentinel lymph node mapping of the ovary: a systematic review. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1209-1215.	2.5	23
17	Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 240, 364-369.	1.1	7
18	Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis. <i>Acta Oncologica</i> , 2019, 58, 790-800.	1.8	28

#	ARTICLE	IF	CITATIONS
19	Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis. <i>Acta Oncologica</i> , 2019, 58, 983-989.	1.8	18
20	Prognostic factors for spontaneous regression of high-risk human papillomavirus-positive cervical intra-epithelial neoplasia grade 2. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1003-1009.	2.5	10
21	Borderline tumours of the ovary: Common practice in the Netherlands. <i>Gynecologic Oncology Reports</i> , 2019, 27, 25-30.	0.6	1
22	Gene Promoter Methylation in Endometrial Carcinogenesis. <i>Pathology and Oncology Research</i> , 2019, 25, 659-667.	1.9	8
23	Patients' information coping styles influence the benefit of a survivorship care plan in the ROGY Care Trial: New insights for tailored delivery. <i>Cancer</i> , 2019, 125, 788-797.	4.1	25
24	Gain of Chromosomal Region 3q26 as a Prognostic Biomarker for High-Grade Cervical Intraepithelial Neoplasia: Literature Overview and Pilot Study. <i>Pathology and Oncology Research</i> , 2019, 25, 549-557.	1.9	7
25	Recurrent Cancer Is Associated With Dissatisfaction With Care—A Longitudinal Analysis Among Ovarian and Endometrial Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 614-622.	2.5	5
26	Interdepartmental Spread of Innovations: A Multicentre Study of the Enhanced Recovery After Surgery Programme. <i>World Journal of Surgery</i> , 2018, 42, 2348-2355.	1.6	4
27	Endometrial cancer survivors' follow-up care (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial. <i>Trials</i> , 2018, 19, 227.	1.6	14
28	Survivorship care plans have a negative impact on long-term quality of life and anxiety through more threatening illness perceptions in gynecological cancer patients: the ROGY care trial. <i>Quality of Life Research</i> , 2018, 27, 1533-1544.	3.1	31
29	The impact of the survivorship care plan on health care use: 2-year follow-up results of the ROGY care trial. <i>Journal of Cancer Survivorship</i> , 2018, 12, 18-27.	2.9	17
30	No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. <i>European Journal of Cancer</i> , 2018, 88, 31-37.	2.8	92
31	Blocking 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. <i>Journal of Pathology</i> , 2018, 244, 203-214.	4.5	21
32	Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery. <i>Frontiers in Pharmacology</i> , 2018, 9, 940.	3.5	42
33	Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2547.	4.1	9
34	Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. <i>European Journal of Cancer</i> , 2018, 100, 55-64.	2.8	5
35	Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 630-638.	7.3	144
36	Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients. <i>Gynecologic Oncology</i> , 2017, 146, 380-385.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Treatment of Cervical Intraepithelial Neoplasia: Patients Preferences for Surgery or Immunotherapy with Imiquimod. <i>Journal of Immunotherapy</i> , 2017, 40, 148-153.	2.4	7
38	Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up â€” The ROGY care trial. <i>Gynecologic Oncology</i> , 2017, 145, 319-328.	1.4	35
39	Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis. <i>Gynecologic Oncology</i> , 2017, 145, 310-318.	1.4	22
40	High mRNA levels of 17Î²-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 442, 51-57.	3.2	27
41	Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 2-2.	2.5	10
42	Comparison of Intraoperative Î³-Probe Imaging and Postoperative SPECT/CT in Detection of Sentinel Nodes Related to the Ovary. <i>Journal of Nuclear Medicine</i> , 2017, 58, 243-245.	5.0	14
43	A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. <i>Human Pathology</i> , 2017, 59, 62-69.	2.0	12
44	Factors influencing implementation of a survivorship care planâ€”a quantitative process evaluation of the ROGY Care trial. <i>Journal of Cancer Survivorship</i> , 2017, 11, 64-73.	2.9	13
45	Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e7.	2.2	28
46	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5502-5502.	1.6	23
47	Predictive criteria for MRI-based evaluation of response both during and after radiotherapy for cervical cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 3, 181-188.	0.9	10
48	Physiciansâ€™ Awareness, Attitudes, and Experiences Regarding Imiquimod Treatment of Vaginal and Cervical Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 75-79.	1.9	6
49	Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 458-466.	7.3	161
50	The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer. <i>European Journal of Cancer</i> , 2016, 66, 83-90.	2.8	42
51	Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer. <i>Diagnostic Pathology</i> , 2016, 11, 34.	2.0	10
52	Bipolar versus balloon endometrial ablation in the office: a randomized controlled trial. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 196, 52-56.	1.1	48
53	Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography. <i>Gynecologic Oncology</i> , 2016, 140, 22-28.	1.4	21
54	Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 58, 17-29.	2.8	172

#	ARTICLE	IF	CITATIONS
55	Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 268-275.	2.5	18
56	Paper-Based Survivorship Care Plans May be Less Helpful for Cancer Patients Who Search for Disease-Related Information on the Internet: Results of the Registrationsystem Oncological Gynecology (ROGY) Care Randomized Trial. <i>Journal of Medical Internet Research</i> , 2016, 18, e162.	4.3	8
57	Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1405-1414.	2.5	53
58	Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care. <i>PLoS ONE</i> , 2015, 10, e0132158.	2.5	109
59	Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis. <i>Radiation Oncology</i> , 2015, 10, 252.	2.7	5
60	Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3550-3559.	1.6	106
61	Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 527-546.	3.1	48
62	External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 210-215.	1.4	28
63	Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands. <i>BMC Cancer</i> , 2015, 15, 482.	2.6	9
64	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 5501-5501.	1.6	2
65	Translabial Three-Dimensional Ultrasonography Compared With Magnetic Resonance Imaging in Detecting Levator Ani Defects. <i>Obstetrics and Gynecology</i> , 2014, 124, 1190-1197.	2.4	34
66	Aggressive Behavior and Poor Prognosis of Endometrial Stromal Sarcomas With YWHAЕ-FAM22 Rearrangement Indicate the Clinical Importance to Recognize This Subset. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1616-1622.	2.5	23
67	The majority of metachronous CIN1 and CIN3 lesions are caused by different human papillomavirus genotypes, indicating that the presence of CIN1 seems not to determine the risk for subsequent detection of CIN3. <i>Human Pathology</i> , 2014, 45, 221-226.	2.0	6
68	Oncology providers'™ evaluation of the use of an automatically generated cancer survivorship care plan: longitudinal results from the ROGY Care trial. <i>Journal of Cancer Survivorship</i> , 2014, 8, 248-259.	2.9	21
69	Mucinous borderline tumours of the ovary and the appendix: A retrospective study and overview of the literature. <i>Gynecologic Oncology</i> , 2014, 133, 155-158.	1.4	30
70	Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCcer trial): a multicenter randomised controlled study. <i>BMC Cancer</i> , 2014, 14, 22.	2.6	37
71	The Detection of Sentinel Nodes in Ovarian Cancer: A Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1799-1804.	5.0	45
72	Diffusion of Enhanced Recovery principles in gynecologic oncology surgery: Is active implementation still necessary?. <i>Gynecologic Oncology</i> , 2014, 134, 570-575.	1.4	54

#	ARTICLE	IF	CITATIONS
73	A family history questionnaire improves detection of women at risk for hereditary gynecologic cancer: a pilot study. <i>Familial Cancer</i> , 2014, 13, 469-475.	1.9	8
74	Survivorship Care Plans to inform the primary care physician: results from the ROGY care pragmatic cluster randomized controlled trial. <i>Journal of Cancer Survivorship</i> , 2014, 8, 595-602.	2.9	38
75	Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: A systematic review. <i>Gynecologic Oncology</i> , 2014, 133, 124-127.	1.4	20
76	Ovarium- en tubacarcinoom. , 2014, , 159-167.		0
77	Sentinel node in ovarian cancer: study protocol for a phase 1 study. <i>Trials</i> , 2013, 14, 47.	1.6	7
78	Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 365-377.	1.6	30
79	Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: A study from the population-based PROFILES registry. <i>Gynecologic Oncology</i> , 2013, 129, 324-331.	1.4	41
80	The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: Survey among Dutch gynecologists and medical oncologists. <i>Gynecologic Oncology</i> , 2013, 131, 561-566.	1.4	5
81	Use of the HPV MLPA assay in cervical cytology for the prediction of high grade lesions. <i>Journal of Medical Virology</i> , 2013, 85, 1386-1393.	5.0	5
82	Does recruitment for multicenter clinical trials improve dissemination and timely implementation of their results? A survey study from the Netherlands. <i>Clinical Trials</i> , 2013, 10, 915-923.	1.6	6
83	Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. <i>BMJ</i> , The, 2013, 347, f5588-f5588.	6.0	413
84	The impact of an automatically generated survivorship care plan on patient reported outcomes (ROGY) Tj ETQq0 0 0 rgBT /Overlock 10 T patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16517-e16517.	1.6	0
85	Overexpression of 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17 $\beta$ -Estradiol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E591-E601.	3.6	62
86	Predicting the Coexistence of an Endometrial Adenocarcinoma in the Presence of Atypical Complex Hyperplasia: Immunohistochemical Analysis of Endometrial Samples. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1264-1272.	2.5	18
87	Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: A large population-based study. <i>Gynecologic Oncology</i> , 2012, 127, 153-160.	1.4	51
88	Comments on "Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer". <i>Molecular and Cellular Endocrinology</i> , 2012, 363, 131-132.	3.2	1
89	Multiple Miscarriages Are Associated with the Risk of Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition. <i>PLoS ONE</i> , 2012, 7, e37141.	2.5	19
90	Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. <i>Gynecologic Oncology</i> , 2012, 125, 649-654.	1.4	43

#	ARTICLE	IF	CITATIONS
91	Should we centralise care for the patient suspected of having ovarian malignancy?. Gynecologic Oncology, 2011, 122, 95-99.	1.4	14
92	The impact of a cancer Survivorship Care Plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials, 2011, 12, 256.	1.6	36
93	Abstract B11: Routine use of a screening questionnaire improves detection of individuals that may be at risk of hereditary cancer. , 2011, , .		0
94	Bipolar Radiofrequency Endometrial Ablation Compared With Hydrothermablation for Dysfunctional Uterine Bleeding. Obstetrics and Gynecology, 2010, 116, 819-826.	2.4	36
95	Para-aortic lymphadenectomy in endometrial cancer. Lancet, The, 2010, 376, 511.	13.7	0
96	Value of Cervical Cytology in Diagnosing Endometrial Carcinoma in Women with Postmenopausal Bleeding. Acta Cytologica, 2009, 53, 277-282.	1.3	12
97	Health-Related Quality of Life in Cervical Cancer Survivors: A Population-Based Survey. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1501-1509.	0.8	133
98	Patients' preferences in mode of surgery of an adnexal mass. Journal of Psychosomatic Obstetrics and Gynaecology, 2009, 30, 162-167.	2.1	3
99	Clinical Value of Morphometric and DNA Flow Cytometric Variables as Independent Predictors of Survival in Epithelial Ovarian Carcinoma: A 5-year Follow-up Study. International Journal of Gynecological Pathology, 2009, 28, 432-441.	1.4	3
100	The Accuracy of Risk Scores in Predicting Ovarian Malignancy. Obstetrics and Gynecology, 2009, 113, 384-394.	2.4	159
101	Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses?. Gynecologic Oncology, 2007, 106, 153-159.	1.4	21
102	Evaluation of Adnexal Masses With Three-Dimensional Ultrasonography. Obstetrics and Gynecology, 2006, 108, 1167-1175.	2.4	44
103	High Concordance of Results of Testing for Human Papillomavirus in Cervicovaginal Samples Collected by Two Methods, with Comparison of a Novel Self-Sampling Device to a Conventional Endocervical Brush. Journal of Clinical Microbiology, 2006, 44, 2518-2523.	3.9	81
104	The impact of size of the adnexal mass on the accuracy of frozen section diagnosis. Gynecologic Oncology, 2005, 99, 362-366.	1.4	25
105	Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecologic Oncology, 2005, 96, 1-9.	1.4	97
106	Role of Magnetic Resonance Imaging in the Diagnosis of Incarceration of the Gravid Uterus. Obstetrics and Gynecology, 2003, 102, 1134-1137.	2.4	33
107	2 Menstruation as the pelvic aggressor. Bailliere's Clinical Obstetrics and Gynaecology, 1993, 7, 687-700.	0.6	14
108	Ovarian Stimulation and Granulosa-Cell Tumour. Obstetrical and Gynecological Survey, 1993, 48, 686.	0.4	0



#	ARTICLE	IF	CITATIONS
109	Epitopes for Endometrial Cells. <i>Fertility and Sterility</i> , 1992, 58, 1267-1268.	1.0	1
110	Immunocytochemical markerprofile of endometriotic epithelial, endometrial epithelial, and mesothelial cells: a comparative study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1991, 41, 215-223.	1.1	29
111	Ruptured vasa praevia indicated by a sinusoidal fetal heart rate pattern: a case report. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1991, 39, 147-150.	1.1	18
112	High CA-125 concentrations in peritoneal fluid of normal cyclic women with various infertility-related factors as demonstrated with two-step immunoradiometric assay. <i>Fertility and Sterility</i> , 1991, 56, 863-869.	1.0	15
113	Endometrial epithelial cells in peritoneal fluid during the early follicular phase. <i>Fertility and Sterility</i> , 1991, 55, 297-303.	1.0	184
114	Retrograde seeding of endometrial epithelial cells by uterine-tubal flushing. <i>Fertility and Sterility</i> , 1991, 56, 414-420.	1.0	32